Consolidated Portfolio Review Corp Raises Stock Position in MetLife, Inc. $MET

Consolidated Portfolio Review Corp boosted its holdings in MetLife, Inc. (NYSE:MET) by 6.8% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 4,846 shares of the financial services provider’s stock after buying an additional 308 shares during the period. Consolidated Portfolio Review Corp’s holdings in MetLife were worth $390,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Csenge Advisory Group increased its stake in MetLife by 1.0% in the 1st quarter. Csenge Advisory Group now owns 13,647 shares of the financial services provider’s stock worth $1,096,000 after buying an additional 131 shares in the last quarter. Delta Investment Management LLC boosted its holdings in shares of MetLife by 0.9% during the 1st quarter. Delta Investment Management LLC now owns 14,265 shares of the financial services provider’s stock valued at $1,145,000 after purchasing an additional 133 shares during the last quarter. Glenview Trust co boosted its holdings in shares of MetLife by 0.4% during the 1st quarter. Glenview Trust co now owns 38,333 shares of the financial services provider’s stock valued at $3,078,000 after purchasing an additional 141 shares during the last quarter. Stock Yards Bank & Trust Co. boosted its holdings in shares of MetLife by 2.5% during the 1st quarter. Stock Yards Bank & Trust Co. now owns 6,463 shares of the financial services provider’s stock valued at $519,000 after purchasing an additional 159 shares during the last quarter. Finally, My Legacy Advisors LLC boosted its holdings in shares of MetLife by 1.2% during the 2nd quarter. My Legacy Advisors LLC now owns 14,000 shares of the financial services provider’s stock valued at $1,097,000 after purchasing an additional 164 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

MetLife Trading Down 0.7%

MET opened at $81.34 on Friday. The firm has a market cap of $54.09 billion, a P/E ratio of 13.79, a P/E/G ratio of 0.74 and a beta of 0.86. MetLife, Inc. has a 12 month low of $65.21 and a 12 month high of $89.05. The company has a current ratio of 0.16, a quick ratio of 0.16 and a debt-to-equity ratio of 0.57. The stock has a 50-day moving average of $79.03 and a 200 day moving average of $78.20.

MetLife (NYSE:MET) last released its quarterly earnings results on Wednesday, August 6th. The financial services provider reported $2.02 EPS for the quarter, missing the consensus estimate of $2.32 by ($0.30). The company had revenue of $17.34 billion during the quarter, compared to analysts’ expectations of $18.58 billion. MetLife had a return on equity of 19.88% and a net margin of 5.83%.The company’s revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.28 EPS. As a group, research analysts forecast that MetLife, Inc. will post 9.65 EPS for the current year.

MetLife Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 5th were paid a dividend of $0.5675 per share. This represents a $2.27 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 5th. MetLife’s dividend payout ratio (DPR) is currently 38.47%.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Wolfe Research raised shares of MetLife to a “strong-buy” rating in a report on Tuesday, September 16th. UBS Group dropped their price objective on shares of MetLife from $94.00 to $91.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Jefferies Financial Group increased their price objective on shares of MetLife from $100.00 to $103.00 and gave the company a “buy” rating in a report on Monday, August 11th. Barclays increased their price objective on shares of MetLife from $88.00 to $94.00 and gave the company an “overweight” rating in a report on Monday, July 7th. Finally, Morgan Stanley lowered their price target on shares of MetLife from $98.00 to $94.00 and set an “overweight” rating for the company in a report on Monday, August 18th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, MetLife currently has an average rating of “Moderate Buy” and an average target price of $94.64.

MetLife Profile

MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.